secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001730463-24-000088
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus Q2 net loss $58.3M; cash $705.9M; obe-cel PDUFA Nov 16, 2024 on track
-----------------------------------------------------------------------------

- Net loss $58.3M ($0.22/sh) vs $45.6M ($0.26/sh) in Q2 2023; cash $705.9M up from $239.6M at Dec 31, 2023.
- Obe-cel PDUFA target action date set at November 16, 2024; BLA under review by FDA.
- FELIX data (median follow-up 21 mos): 40% of responders in ongoing remission without subsequent stem cell transplant.
- MAA submitted to UK MHRA July 2024; EMA MAA accepted April 2024.
- R&D expenses $36.6M, G&A $21.9M, both up on pre-commercialization activities and new manufacturing facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000088/0001730463-24-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000088/autl-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer